MedPath

A Study of the Safety and Tolerance of Long-Term Therapy With Intravenous Cytovene (Ganciclovir Sodium) for Cytomegalovirus Retinitis in Persons With AIDS

Not Applicable
Completed
Conditions
Cytomegalovirus Retinitis
HIV Infections
Registration Number
NCT00002034
Lead Sponsor
Hoffmann-La Roche
Brief Summary

To evaluate the safety and tolerance of long-term ganciclovir (DHPG) therapy for newly diagnosed macular threatening Cytomegalovirus (CMV) retinitis in AIDS patients. To evaluate the clinical response to a 52 week course of intravenous DHPG therapy. To evaluate the safety and tolerance of long-term DHPG with concurrent treatment with zidovudine (AZT). (Patients utilizing treatment with other anti-retroviral drugs will be considered for study entry on a case by case basis.) To determine survival in this group of patients with AIDS and CMV retinitis.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Summitt Med Ctr / San Francisco Gen Hosp

🇺🇸

Oakland, California, United States

Stanford at Kaiser / Kaiser Permanente Med Ctr

🇺🇸

San Francisco, California, United States

Miami Veterans Administration Med Ctr

🇺🇸

Miami, Florida, United States

Dr Winkler Weinberg

🇺🇸

Roswell, Georgia, United States

SUNY / Health Sciences Ctr at Stony Brook

🇺🇸

Stony Brook, New York, United States

Dr Alfred F Burnside Jr

🇺🇸

Columbia, South Carolina, United States

Univ TX Galveston Med Branch

🇺🇸

Galveston, Texas, United States

Southern Alberta HIV Clinic / Foothills Hosp

🇨🇦

Calgary, Alberta, Canada

Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.